title: Irinotecan chemotherapy associated with transient dysarthria and aphasia.
authors.forename: S
authors.initials: S
authors.lastname: De Marco
authors.forename: E
authors.initials: E
authors.lastname: Squilloni
authors.forename: L
authors.initials: L
authors.lastname: Vigna
authors.forename: M F
authors.initials: MF
authors.lastname: Bertagnolio
authors.forename: C N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001037:Aphasia / Q000139:chemically induced*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D004401:Dysarthria / Q000139:chemically induced*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007260:Infusion Pumps; D000077146:Irinotecan; D008297:Male
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin